The Food and Drug Administration has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn disease in adults.
Celltrion, a leading Korean biotechnology firm, has successfully developed Zymfentra, a subcutaneous version of the company’s ...
An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving ...
A real-world study in adolescent and young adult patients with inflammatory bowel disease (IBD) found no significant ...